Roche/Exelixis' Cotellic fizzles in pivotal melanoma study
To little surprise, Exelixis’ Cotellic — known chemically as cobimetinib — in combination with Roche’s Tecentriq, has failed a late-stage study as a frontline treatment for patients with a form of advanced melanoma.
The Alameda, California-based company’s $EXEL kinase inhibitor — out-licensed to Roche — was approved in 2015 in combination with the Swiss drugmaker’s Zelboraf (vemurafenib) for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. Cotellic generated roughly $61 million in global sales last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.